Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Trillium Therapeutics stock | $17.91

Learn how to easily invest in Trillium Therapeutics stock.

Shares of Trillium Therapeutics jumped above $17 on Aug. 23 on word Pfizer would buy the Canadian drug developer in a $2.3 billion deal.

Trillium Therapeutics Inc is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars. Trillium Therapeutics employs 33 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Trillium Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TRIL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Trillium Therapeutics stock price (NASDAQ: TRIL)

Use our graph to track the performance of TRIL stocks over time.

Trillium Therapeutics shares at a glance

Information last updated 2021-10-25.
Latest market close$17.91
52-week range$5.80 - $20.96
50-day moving average $17.56
200-day moving average $11.37
Wall St. target price$19.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.50

Buy Trillium Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Trillium Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trillium Therapeutics price performance over time

Historical closes compared with the close of $17.91 from 2021-10-25

1 week (2021-10-20) 0.90%
1 month (2021-09-27) 1.02%
3 months (2021-07-27) 174.27%
6 months (2021-04-27) 94.25%
1 year (2020-10-27) 41.58%
2 years (2019-10-25) 6,548.11%
3 years (2018-10-26) 487.21%
5 years (2016-10-27) 25.24%

Trillium Therapeutics financials

Revenue TTM $43,000
Gross profit TTM $148,000
Return on assets TTM -15.6%
Return on equity TTM -29.91%
Profit margin 0%
Book value $2.33
Market capitalisation $1.9 billion

TTM: trailing 12 months

Shorting Trillium Therapeutics shares

There are currently 2.4 million Trillium Therapeutics shares held short by investors – that's known as Trillium Therapeutics's "short interest". This figure is 14.8% down from 2.8 million last month.

There are a few different ways that this level of interest in shorting Trillium Therapeutics shares can be evaluated.

Trillium Therapeutics's "short interest ratio" (SIR)

Trillium Therapeutics's "short interest ratio" (SIR) is the quantity of Trillium Therapeutics shares currently shorted divided by the average quantity of Trillium Therapeutics shares traded daily (recently around 1.9 million). Trillium Therapeutics's SIR currently stands at 1.28. In other words for every 100,000 Trillium Therapeutics shares traded daily on the market, roughly 1280 shares are currently held short.

However Trillium Therapeutics's short interest can also be evaluated against the total number of Trillium Therapeutics shares, or, against the total number of tradable Trillium Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trillium Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Trillium Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.023% of the tradable shares (for every 100,000 tradable Trillium Therapeutics shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trillium Therapeutics.

Find out more about how you can short Trillium Therapeutics stock.

Trillium Therapeutics share dividends

We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.

Have Trillium Therapeutics's shares ever split?

Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.

Trillium Therapeutics share price volatility

Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $5.8 up to $20.96. A popular way to gauge a stock's volatility is its "beta".

TRIL.US volatility(beta: 1.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9823. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Trillium Therapeutics overview

Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc.

Frequently asked questions

What percentage of Trillium Therapeutics is owned by insiders or institutions?
Currently 5.817% of Trillium Therapeutics shares are held by insiders and 84.933% by institutions.
How many people work for Trillium Therapeutics?
Latest data suggests 33 work at Trillium Therapeutics.
When does the fiscal year end for Trillium Therapeutics?
Trillium Therapeutics's fiscal year ends in December.
Where is Trillium Therapeutics based?
Trillium Therapeutics's address is: 100 Cambridgepark Drive, Cambridge, MA, United States, 02140
What is Trillium Therapeutics's ISIN number?
Trillium Therapeutics's international securities identification number is: CA89620X5064
What is Trillium Therapeutics's CUSIP number?
Trillium Therapeutics's Committee on Uniform Securities Identification Procedures number is: 89620X100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site